Roche's RoACTEMRA Reportedly Improves RA Signs, Symptoms

Recent study data shows that the rheumatoid arthritis drug demonstrates more successful results than adalimumab as a single-agent therapy.

Roche's RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy

Roche today announced data from the ADACTA study which showed that adult rheumatoid arthritis (RA) patients who received RoACTEMRA (tocilizumab) as single-agent therapy (without other DMARDs) experienced a significantly greater improvement in disease activity (DAS28 score reduction 1 ) after 24 weeks compared to patients who received adalimumab as single-agent therapy. The results of ADACTA will be presented on Friday at the annual European League Against Rheumatism (EULAR) conference in Berlin.

RA patients are often treated with a number of medicines, combining protein-based biologic therapies with methotrexate (MTX). However, about 1 in 3 patients on a biologic treatment such as RoACTEMRA or adalimumab receive it as a single agent, also known as biologic monotherapy, largely due to intolerance to MTX 1,2,3,4 .

"Since there are a number of therapies approved for patients with RA, it is important for them and their healthcare provider to have the information they need to choose the best individual treatment option," said Hal Barron, M.D., Head of Global Product Development and Chief Medical Officer at Roche. "This study showed that for patients requiring biologic monotherapy RoACTEMRA was more effective than adalimumab, meaning that patients were more likely to experience DAS28 remission, greater improvement in joint pain and swelling, and an improved quality of life."

Results from ADACTA showed that after 24 weeks of treatment patients with severe active RA and intolerance or inadequate response to MTX:

achieved a mean improvement in disease activity (DAS28 score reduction) of 3.3 with RoACTEMRA versus 1.8 with adalimumab had a DAS28 remission rate of 40% with RoACTEMRA versus 11% with adalimumab.

Source: M2 PressWIRE

No votes yet